Myriad Genetics, Inc.
MYGNNASDAQHealthcareDiagnostics & Research
As of Oct 15, 2026 close
- Market cap
- $412.38M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $2.74$8.59
- Volume (live)
- -
- Avg. volume (3M)
- 1.96M
Myriad Genetics (MYGN) Stock Price & Financial Analysis
Myriad Genetics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $4.11 - $4.42 |
|---|---|
| 52-Week High | $8.59 |
| 52-Week Low | $2.74 |
| Open | $4.20 |
| Volume (last close) | 1.07M |
| Average Volume (3M) | 1.96M |
| Revenue (TTM) | 806.60M |
|---|---|
| Net Income (TTM) | -112.60M |
| Free Cash Flow (TTM) | -12.00M |
| EPS (TTM) | −$1.20 |
| Profit Margin | -13.96% |
| Operating Margin | -12.22% |
| Return on Equity (ROE) | -37.05% |
| Debt to Equity | 0.69 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Last Dividend Ex-Date | Jul 1, 2009 |
| Market Cap | 412.38M |
|---|---|
| Shares Outstanding | 94.80M |
| Price to Sales (P/S) | 0.51 |
| Price to Book (P/B) | 1.36 |
| EV/EBITDA | -11.23 |
| 50-Day MA | $3.63 |
|---|---|
| 200-Day MA | $4.65 |
| 1-Year Change | −46.16% |
Source: Market prices and company fundamentals. Data as of Oct 15, 2026. Data sources and methodology
Myriad Genetics at a Glance
As of the Oct 15, 2026 close, Myriad Genetics (MYGN) has a market capitalization of $412.38M. The stock trades at 0.5× sales. Over the trailing twelve months it lost $112.60M on revenue of $806.60M and burned $12.00M of free cash flow. Revenue fell 3.2% year over year.
As of its latest reported balance sheet, it holds $115.20M in cash and securities against $210.50M of debt, a net debt position of $95.30M.
Myriad Genetics does not currently pay a dividend.
The share price is down 46.2% over the past year. At $4.35 (the Oct 15, 2026 close) it sits within its 52-week range of $2.74 to $8.59, below its 200-day moving average of $4.65.
Based on 9 professional analyst ratings from the past 90 days, the consensus is Hold with an average price target of $3.76, 13.6% below the Oct 15, 2026 close.
Frequently Asked Questions About Myriad Genetics
What is the current stock price for MYGN?
As of the Oct 15, 2026 close, MYGN stock trades at $4.35. The 52-week range is $2.74–$8.59, with a day range of $4.11–$4.42.
What is the P/E ratio for MYGN?
The P/E ratio (Price-to-Earnings) for MYGN is shown in the Key Statistics section. This valuation metric helps compare Myriad Genetics, Inc. to industry peers.
Does MYGN pay dividends?
Myriad Genetics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for MYGN?
Based on ratings from 9 professional analysts over the last 90 days, the consensus for MYGN is Hold. The average 12-month price target is $3.76, a 13.6% downside from the Oct 15, 2026 close of $4.35.
What is the market cap of MYGN?
As of the Oct 15, 2026 close, Myriad Genetics's market capitalization is $412.4M, classifying it as a small-cap company. Myriad Genetics operates in the Healthcare sector within the Diagnostics & Research industry.